Shares of Interpace Diagnostics Group Inc (NASDAQ:IDXG) have earned a consensus recommendation of “Buy” from the six brokerages that are currently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $3.56.
Several equities analysts have commented on IDXG shares. HC Wainwright reissued a “buy” rating and set a $3.00 target price on shares of Interpace Diagnostics Group in a research report on Wednesday, February 20th. Maxim Group restated a “buy” rating and set a $4.00 price target on shares of Interpace Diagnostics Group in a report on Wednesday, March 20th.
A number of hedge funds have recently added to or reduced their stakes in the business. Sio Capital Management LLC bought a new stake in shares of Interpace Diagnostics Group in the first quarter valued at about $1,322,000. Perkins Capital Management Inc. lifted its stake in shares of Interpace Diagnostics Group by 86.4% in the first quarter. Perkins Capital Management Inc. now owns 1,922,250 shares of the business services provider’s stock valued at $1,538,000 after buying an additional 891,250 shares during the period. JPMorgan Chase & Co. bought a new stake in shares of Interpace Diagnostics Group in the third quarter valued at about $194,000. Essex Investment Management Co. LLC lifted its stake in shares of Interpace Diagnostics Group by 12.4% in the fourth quarter. Essex Investment Management Co. LLC now owns 339,678 shares of the business services provider’s stock valued at $272,000 after buying an additional 37,506 shares during the period. Finally, Northern Trust Corp lifted its stake in shares of Interpace Diagnostics Group by 27.4% in the first quarter. Northern Trust Corp now owns 88,246 shares of the business services provider’s stock valued at $70,000 after buying an additional 19,001 shares during the period. Institutional investors own 14.40% of the company’s stock.
Interpace Diagnostics Group (NASDAQ:IDXG) last posted its earnings results on Monday, May 13th. The business services provider reported ($0.10) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.03). The business had revenue of $6.01 million for the quarter, compared to analyst estimates of $6.10 million. Interpace Diagnostics Group had a negative return on equity of 34.69% and a negative net margin of 53.75%. Equities research analysts forecast that Interpace Diagnostics Group will post -0.22 EPS for the current year.
Interpace Diagnostics Group Company Profile
Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.
Featured Story: What is Depreciation?
Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.